This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Today's Health Winners and Losers

Shares of Thoratec (THOR - Get Report) were among the worst-performing health-related stocks Wednesday, tumbling 21% after the maker of heart disease products issued a 2006 forecast that fell below Wall Street expectations.

The company's fourth-quarter results topped forecasts. Thoratec earned $4.5 million, or 8 cents a share, on sales of $54.8 million. Excluding items, the company earned $8.9 million, or 16 cents a share. Analysts polled by Thomson First Call expected earnings of 11 cents a share, before items, on sales of $53 million. A year earlier, Thoratec posted adjusted earnings of $6 million, or 12 cents a share, on sales of $48.3 million.

For 2006, Thoratec sees earnings of $22 million to $24 million, or 40 cents to 44 cents a share, before items. Analysts project earnings of 48 cents a share. The company forecast sales of $217 million to $225 million, short of Wall Street's target of $227.2 million. Shares were trading down $5.30 to $20.

GeoPharma (GORX) jumped 12% after the pharmaceutical company said it swung to a third-quarter profit and reported an 80% increase in sales. The company earned $365,000, or 3 cents a share, on sales of $12.4 million, for the quarter ended Dec. 31. During the year-ago quarter, the company posted a loss of $960,000, or 12 cents a share, on sales of $6.9 million. Shares were up 56 cents to $5.31.

Candela (CLZR) soared 30% after the medical laser maker posted better-than-expected fiscal second-quarter results. Candela's income for the December period rose to $4.5 million, or 19 cents a share, from $1.7 million, or 7 cents a share, a year earlier. Analysts polled by Thomson First Call were expecting earnings of 12 cents a share. The company's second-quarter revenue jumped 34% to $37.7 million, beating analysts' target of $33.4 million. Candela shares were up $4.38 to $19.35.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AMGN $167.91 0.00%
MOH $63.85 0.00%
PG $81.00 0.00%
THOR $42.31 0.00%
TEVA $64.41 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs